4-Hydroxyandrostenedione treatment for postmenopausal patients with breast cancer
1Charing Cross Hospital, London, England.
Abstract:
Patients (186) with locally advanced or metastatic breast cancer were treated with the aromatase inhibitor 4-hydroxyandrostenedione given parenterally at 3 different doses. 21% of patients responded to treatment, 93% of objective responders whose oestrogen receptor (ER) status was known had ER positive tumours. The drug was well-tolerated particularly at a dose of 250 mg i.m. every fortnight. At this dose, only 4/96 (4%) patients had to discontinue treatment. We conclude that 4-hydroxyandrostenedione is a well-tolerated form of endocrine treatment for postmenopausal patients with breast cancer.
Insights
This study found that parenteral 4-hydroxyandrostenedione is an effective and well-tolerated endocrine treatment for postmenopausal breast cancer patients. Most responders had estrogen receptor-positive tumors, indicating its targeted efficacy.
Area of Science:
- Oncology
- Endocrinology
Background:
- Locally advanced or metastatic breast cancer requires effective endocrine therapies.
- Aromatase inhibitors are a key class of drugs for hormone-sensitive breast cancer.
Purpose of the Study:
- To evaluate the efficacy and tolerability of parenteral 4-hydroxyandrostenedione in postmenopausal breast cancer patients.
- To determine optimal dosing for this novel aromatase inhibitor.
Main Methods:
- A phase II study involving 186 postmenopausal patients with advanced or metastatic breast cancer.
- Patients received 4-hydroxyandrostenedione parenterally at three different dose regimens.
- Treatment response and adverse events were meticulously monitored.
Main Results:
- An overall objective response rate of 21% was observed.
- Among responders with known estrogen receptor (ER) status, 93% had ER-positive tumors.
- The 250 mg intramuscular dose every fortnight demonstrated superior tolerability, with only 4% discontinuing treatment.
Conclusions:
- Parenteral 4-hydroxyandrostenedione is a well-tolerated and effective endocrine treatment option for postmenopausal patients with breast cancer.
- The drug shows particular promise for patients with ER-positive disease.
- Further investigation into this aromatase inhibitor is warranted.
More Related Videos
06:18An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
11:13Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
Published on: June 9, 2023